PGR and neoplasm: In patients with ER-positive and PgR-positive tumours, a subset likely to be sensitive to the positive benefits of endocrine treatments, a retrospectively derived analysis of the data was suggestive of a possible benefit for fulvestrant compared with tamoxifen in terms of OR.